haya therapeutics

HAYA Therapeutics develops programmable RNA-guided therapies designed to reverse disease-driving cell states by targeting the regulatory genome, or non-coding RNA. The company utilizes a platform that integrates multimodal functional genomics with computational tools to identify and drug the non-coding regions of the genome that causally drive disease. Their current pipeline includes therapeutic applications for chronic diseases, including a Phase 1 clinical trial for their candidate HTX-001.